Engflag
Advertisements

Pantocid DSR

Quick links to important sections

Pantocid DSR

Pantocid DSR_EN
Advertisements
Advertisements

Method of action: Antiulcer, Drugs For Acid Related Disorders, Proton Pump Inhibitor

Treatment option: Gastroesophageal Reflux Disease, Hypersecretory Conditions, Heartburn, Pathological Hypersecretory Conditions, Reflux, Zollinger-Ellison Syndrome, Esophagitis, Erosive Esophagitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Pantocid DSR

What is Pantocid DSR?

Pantocid DSR is a fixed-dose combination medication composed of two active ingredients: Pantoprazole and Domperidone. It is primarily utilized in the management of gastrointestinal conditions characterized by excessive acid production and impaired motility.

Components and Mechanism

The medication works through the synergistic action of its two primary components:

  • Pantoprazole: This ingredient belongs to a class of drugs known as proton pump inhibitors (PPIs). It functions by targeting the gastric proton pumps in the stomach lining, effectively reducing the secretion of hydrochloric acid. This helps in alleviating symptoms related to acidity and allows the esophageal and gastric tissues to heal.
  • Domperidone: Classified as a prokinetic and anti-dopaminergic agent, domperidone works by increasing the movements or contractions of the stomach and intestines. It also acts on the chemoreceptor trigger zone to help suppress feelings of nausea.

Therapeutic Use

As a sustained-release (SR) formulation, Pantocid DSR is designed to provide a steady release of medication over a prolonged period. The combination is typically used to address several gastrointestinal issues, including:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the tube connecting the mouth and stomach, often causing heartburn.
  • Peptic Ulcer Disease: The management of sores that develop on the lining of the stomach, lower esophagus, or small intestine.
  • Dyspepsia: Relief from chronic indigestion or upper abdominal discomfort, particularly when associated with delayed gastric emptying or nausea.

By combining an acid-reducer with a prokinetic agent, the medication addresses both the chemical (acid) and mechanical (motility) aspects of acid-related digestive disorders.

Regulatory References

  1. MedlinePlus, Pantoprazole
  2. NIH Study on Fixed-Dose Combination
Advertisements

What side effects are possible with Pantocid DSR?

Possible Side Effects and Safety Information

The safety profile of this medicine, combining Pantoprazole and Domperidone, is defined by officially documented adverse reactions classified by frequency and affected physiological systems, as detailed in governmental regulatory sources.

Officially Classified Adverse Reactions

The adverse reactions associated with this fixed-dose combination are categorized into frequency bands and System-Organ Classes (SOC) in regulatory documents. Common reactions often include headache, diarrhea, abdominal pain, nausea, and flatulence. Effects classified as Uncommon may include dizziness, skin rash, and fatigue. More systemic and serious reactions are typically classified as Rare or Very Rare, based on post-marketing surveillance.

Classification Affected System (Examples)
Common Gastrointestinal Disorders, Nervous System Disorders
Rare/Very Rare Cardiac Disorders, Severe Cutaneous Reactions, Blood Disorders

Serious Adverse Reactions and Restrictions

Official regulatory information highlights the potential for serious adverse reactions. The Domperidone component is associated with risks of severe cardiac arrhythmias, including QT prolongation and Torsade de Pointes, which can lead to sudden cardiac death. Due to this risk, the medicine is contraindicated in patients with pre-existing cardiac conduction abnormalities or significant electrolyte imbalances, and in those taking other medicines that prolong the QT interval.

Population and Duration-Related Safety Patterns

The label defines specific population-specific restrictions, notably the contraindication for use in individuals with moderate to severe hepatic impairment. Furthermore, long-term use (typically one year or longer) of the Pantoprazole component is officially associated with specific risks. These include an increased likelihood of bone fracture (hip, wrist, or spine), the development of fundic gland polyps, and the potential for developing hypomagnesemia (low magnesium levels).

This structured safety profile establishes the formal, regulatory basis for understanding the medicine's risks, separating frequently occurring non-severe events from rare, but potentially serious, systemic constraints.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented signs and required emergency actions in case of an overdosage with Pantocid DSR (Pantoprazole/Domperidone), strictly based on government regulatory labeling.

Documented Manifestations and Serious Outcomes

Overdosage with the Domperidone component may present with central nervous system effects, including drowsiness, disorientation, and extrapyramidal reactions. Symptoms for the Pantoprazole component are generally reported as being within its known safety profile. However, regulatory warnings note that an overdosage carries a risk of serious ventricular arrhythmias and sudden cardiac death due to the Domperidone component.

Required Emergency Actions

In the event of suspected overdosage, close medical supervision and supportive therapy are required, and individuals must seek immediate medical attention. The official instructions specify that gastric lavage should be performed, and the administration of activated charcoal may be useful as part of supportive measures. No specific antidote is known for the Domperidone component. Notably, extrapyramidal reactions are documented as occurring especially in children following Domperidone overdosage, and Pantoprazole is not removed by hemodialysis.

Advertisements

Therapeutic Uses of Pantocid DSR

The combination is generally used in situations involving certain distressing symptoms related to both acid and functional digestive issues. The combination is commonly used as part of the symptomatic management for conditions like Gastroesophageal Reflux Disease (GERD), erosive esophagitis, and Peptic Ulcer Disease. This medicine is applied across domains where additional symptomatic support is needed to address symptoms that may become more noticeable, such as chronic heartburn, acid regurgitation, upper abdominal discomfort, and nausea. It helps manage symptom clusters that may become intense or disruptive, especially those associated with delayed stomach emptying, such as bloating and persistent fullness after eating.

“This approach supports the patient during difficult episodes and contributes to easing the overall symptom load associated with chronic acid and motility issues.”

Quick Fact: Relief for Combined GI Distress

This formulation may be part of symptomatic management in conditions where patients experience a combination of acid-related pain and discomfort related to functional digestive issues. It assists with maintaining functional stability and contributes to the healing of acid-damaged tissue.

Regulatory References

  1. Nigerian National Agency for Food and Drug Administration and Control (NAFDAC)
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Pantocid DSR?

Pantocid DSR is a combination medication containing Pantoprazole (a proton pump inhibitor) and Domperidone (a prokinetic agent). Its use is generally intended for adults and adolescents for conditions such as gastroesophageal reflux disease (GERD) and dyspepsia, where both reduced acid production and improved gut motility are desired.

Contraindications

The medication is contraindicated (should not be used) in patients with specific medical conditions or drug sensitivities. This is primarily due to the Domperidone component, which carries risks related to heart function.

Condition/Category Reason for Contraindication
Heart Conditions Patients with moderate to severe hepatic impairment, pre-existing cardiac conditions (e.g., heart failure, known prolonged QT interval), or significant electrolyte disturbances (e.g., hypokalemia) due to the risk of serious ventricular arrhythmias.
Gastrointestinal Issues Patients with conditions where stimulating gut motility may be harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation.
Drug Interactions Concomitant use with strong CYP3A4 inhibitors (e.g., certain antifungals, macrolide antibiotics) which can increase Domperidone levels and the risk of QT prolongation.
Age Generally not recommended for children due to insufficient data on safety and efficacy.

Always consult a healthcare professional to determine if Pantocid DSR is appropriate and safe for your specific health profile.

Advertisements

What should I know about interactions with other medicines?

This combination medicine contains pantoprazole and domperidone, and its interaction profile is structured around the properties of both drugs.

Contraindicated and High-Risk Combinations

Do not co-administer this product with medicines that may substantially prolong the QT interval on an electrocardiogram, as the domperidone component increases this cardiac risk. This includes certain antifungals, some antibiotics, and other specific medicines. The use of this product is contraindicated with potent inhibitors of the CYP3A4 enzyme (such as certain macrolide antibiotics and HIV protease inhibitors) and with HIV medications containing rilpivirine, as pantoprazole significantly reduces the absorption and efficacy of rilpivirine.

Interactions Requiring Monitoring

  • Anticoagulants (e.g., warfarin): Close monitoring of the International Normalized Ratio ( INR) is officially required upon initiation or cessation of this product, as concomitant use may increase the risk of bleeding.
  • Methotrexate: Co-administration, particularly with high-dose methotrexate, may elevate and prolong methotrexate plasma levels, potentially leading to toxicity. Monitoring is necessary.
  • Acid-Dependent Drugs: Pantoprazole reduces stomach acid, which can decrease the absorption and effectiveness of drugs that require an acidic pH for proper absorption (e.g., ketoconazole, itraconazole, erlotinib).
  • CNS Depressants: Domperidone may enhance the effects of CNS depressants, especially in certain populations like the elderly.
Advertisements

Mechanism of Action

Mechanism of Action

The drug's mechanism involves two distinct pharmacodynamic actions: irreversible enzyme inhibition in acid production and peripheral receptor antagonism affecting gastrointestinal motility.

Irreversible Blockade of Gastric Acid Pumps

This component reduces acid load by acting as a specific, irreversible inhibitor of the H^+/ K^+-ATPase enzyme, or Proton Pump, which constitutes the final molecular step in releasing hydrochloric acid ( HCl) into the stomach lumen. The active Pantoprazole metabolite forms a covalent bond with the pump, leading to its sustained inactivation and a long-acting suppression of hydrochloric acid secretion, regardless of the upstream physiological stimulus.

Peripheral Modulation of Dopamine Receptor Signaling

The prokinetic component acts as a selective antagonist of peripheral Dopamine D2 and D3 receptors in the gut and the Chemoreceptor Trigger Zone ( CTZ). Blocking these receptors indirectly enhances the release of the neurotransmitter acetylcholine in the enteric nervous system, leading to stronger, coordinated smooth muscle contractions and increased Lower Esophageal Sphincter ( LES) tone. This mechanism physiologically accelerates gastric emptying and facilitates physical clearance in the upper digestive tract.

Mechanistic Synergy for Dual Control

The combined action results from Pantoprazole suppressing acid production and Domperidone modulating motility and clearance. This dual mechanism physiologically regulates both the acid environment and the kinetic function of the upper digestive tract.

Advertisements

Dosage and Administration Information

How to Use Pantocid DSR — Administration Guidelines

This section outlines the administration instructions for Pantocid DSR (a combination product containing Pantoprazole 40 mg enteric-coated and Domperidone 30 mg sustained-release). Adherence to these steps is required for proper use.

Administration Details

Field Instruction
Route of Administration Oral (by mouth).
Standard Dosing One hard capsule.
Frequency and Timing Once daily, taken in the morning.
Relation to Meals Must be taken on an empty stomach or 30 to 60 minutes before the first meal of the day (typically breakfast).

Procedural and Structural Rules

To ensure the functional integrity of the sustained-release (SR) and enteric-coated (EC) pellets, the following steps must be strictly observed:

  • Swallowing: The capsule must be swallowed whole with a glass of water. It must not be chewed, crushed, split, or opened.
  • Missed Dose: If a dose is missed, take it as soon as remembered, unless it is nearly time for the next scheduled dose. If so, skip the missed dose and continue the regular schedule. Do not take a double dose.
  • Duration: The medicine should be taken for the full course prescribed by the physician. Do not discontinue use prematurely, even if symptoms improve.

Population-Specific Caution

Caution and potential dose adjustment may be necessary for use in elderly patients and individuals with significant hepatic or renal impairment.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence for Combination Therapy

Pantocid DSR is a fixed-dose combination of Pantoprazole (a proton pump inhibitor) and Domperidone (a prokinetic agent). Clinical research focuses on evaluating the additive effect of including a prokinetic agent alongside standard acid suppression therapy for managing acid reflux disease (GERD) and functional dyspepsia.

Studies have assessed the efficacy of this combination, particularly in patients whose symptoms are not fully relieved by a proton pump inhibitor (PPI) alone, often termed refractory GERD. While PPIs effectively reduce stomach acid production, the addition of Domperidone aims to influence symptoms related to delayed gastric emptying, such as nausea and bloating.

Area of Research Key Study Findings (Reported Outcomes)
Symptom Improvement Some trials and meta-analyses suggest that combination therapy may be associated with a greater reduction in overall GERD symptoms (heartburn, regurgitation) compared to PPI monotherapy.
Gastric Motility Domperidone's inclusion has been shown in some studies to improve the movement of food from the stomach to the intestines, addressing a potential underlying factor in dyspepsia.
Healing Rates The rates of endoscopic healing for erosive esophagitis (damage to the food pipe) are generally found to be high with PPIs, and the combination therapy's effect on final healing rates often mirrors that of Pantoprazole alone.
Quality of Life Research investigating the impact on patient quality of life scores following the combination therapy has yielded mixed results, with some studies reporting improvements and others finding no significant difference compared to PPI-only treatment.

Trial results consistently include data on the incidence of adverse events and safety profiles for both components. Specific cautionary data relating to the cardiovascular risk profile of Domperidone are noted in clinical documentation, mandating the use of the lowest effective dose for the shortest possible duration.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pantocid DSR (FAQ)

Q: What is Pantocid DSR?

A: Pantocid DSR is a combination product that features a proton pump inhibitor, pantoprazole, and a prokinetic agent, domperidone. It is generally utilized for conditions involving excess stomach acid and movement disorders of the stomach and upper gut.

Q: How does Pantocid DSR function in the body?

A: The pantoprazole component is understood to work by reducing the amount of acid produced in the stomach. The domperidone component is generally understood to help with the movement of food through the digestive tract.

Q: What conditions is Pantocid DSR associated with?

A: This product is most commonly associated with the management of gastroesophageal reflux disease (GERD) and conditions like acid reflux and persistent heartburn. Its use is based on the components' combined effects on acid production and gastric motility.

Advertisements

How should Pantocid DSR be stored and disposed of?

How to Store and Dispose of Pantocid DSR?

This section details the mandatory storage and disposal rules for Pantocid DSR (Pantoprazole 40mg / Domperidone 30mg capsule) as strictly defined by official regulatory labeling to maintain the product's integrity.

Official Storage Requirements

The capsules must be stored in a cool, dry place at a temperature not exceeding 30 C or below 25 C depending on the specific regional label. It is required to keep the medication in its original container, protected from light and moisture, and placed out of the sight and reach of children and pets. Storage environments with excess heat or humidity must be avoided, such as a bathroom.

Official Disposal Instructions

Disposal of any unused or expired Pantocid DSR must adhere to local requirements and pharmaceutical waste regulations. The medicine must not be flushed down the toilet or poured down a drain unless explicitly authorized by regulatory guidance. When a drug take-back program is unavailable, follow official guidelines for disposal in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagMyanmar

Equivalent of Pantocid DSR found in:

A-Z Index: